Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New product for brow furrows launched in the US and the UK

This article was originally published in Scrip

Executive Summary

Medicis has launched Dysport (abobotulinumtoxinA) in the US for the treatment of glabellar lines. The drug, an acetylcholine release inhibitor and a neuromuscular blocking agent, achieved regulatory approval for this indication from both the US FDA and EU authorities earlier this year. The FDA also approved Dysport for cervical dystonia, and Ipsen will launch the product in the US later this year for this indication. The product has also been launched in the UK, as Azzalure, by Galderma, also for glabellar lines. In the UK, its wholesale price is £41 per 125 unit vial. The product has been marketed as Dysport in the UK by Ipsen since the 1990s for medical indications such as blepharospasm.

You may also be interested in...



Pfizer's tanezumab hits a nerve (growth factor)

Experimental drugs rarely face setbacks because they are too effective, but Pfizer's novel nerve growth factor antagonist tanezumab might number among the unlucky few. Phase II data presented this week in the NEJM show that the monoclonal antibody relieved osteoarthritic pain, but an accompanying editorial proposed that in doing so the analgesic enables physical activity that can lead to excessive wear and tear on fragile joints.

AstraZeneca moves syk kinase inhibitor into Phase III trials

AstraZeneca has enrolled the first patient in the pivotal programme for the first-in-class Syk kinase inhibitor fostamatinib (previously known as R778). Fostamatinib, which it licensed from Rigel Pharmaceuticals, is being evaluated as a treatment for rheumatoid arthritis (RA) in patients with an inadequate response to disease modifying anti-rheumatic drugs (DMARDs), including methotrexate (MTX).

Michael J. Fox foundation to spend $40 million on search for Parkinson's biomarkers

The Michael J. Fox foundation has launched a $40 million, 5-year initiative to identify biomarkers of Parkinson's disease progression. The scheme, called the Parkinson's Progression Markers Initiative (PPMI), will be carried out at 18 sites in the US and the EU, and will track 400 patients with newly diagnosed disease as well as 200 who do not have the disease.

Topics

Related Companies

UsernamePublicRestriction

Register

SC002760

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel